| Cancer-related molecular mechanisms research | Lifetime | 49 | CN 19 | 99.68 |
| Circular RNAs in diseases | Lifetime | 26 | CN 12 | 99.62 |
| Ferroptosis and cancer prognosis | Lifetime | 20 | CN 6 | 99.51 |
| MicroRNA in disease regulation | Lifetime | 97 | CN 29 | 99.47 |
| RNA modifications and cancer | Lifetime | 154 | CN 11 | 99.53 |
| Cancer-related gene regulation | Lifetime | 102 | CN 6 | 99.23 |
| Ubiquitin and proteasome pathways | Lifetime | 200 | CN 13 | 98.97 |
| Histone Deacetylase Inhibitors Research | Lifetime | 143 | CN 7 | 98.44 |
| Extracellular vesicles in disease | Lifetime | 207 | CN 63 | 97.89 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 157 | CN 5 | 97.81 |
| RNA Research and Splicing | Lifetime | 702 | CN 22 | 98.10 |
| Galectins and Cancer Biology | Lifetime | 224 | CN 3 | 97.40 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 637 | CN 6 | 98.40 |
| Epigenetics and DNA Methylation | Lifetime | 984 | CN 97 | 97.88 |
| Lymphoma Diagnosis and Treatment | Lifetime | 718 | CN 9 | 98.31 |
| Cancer Mechanisms and Therapy | Lifetime | 268 | CN 37 | 97.25 |
| CAR-T cell therapy research | Lifetime | 797 | CN 17 | 97.90 |
| Peptidase Inhibition and Analysis | Lifetime | 934 | CN 29 | 97.14 |
| Kruppel-like factors research | Lifetime | 225 | CN 21 | 95.50 |
| Protein Degradation and Inhibitors | Lifetime | 567 | CN 27 | 96.05 |
| Viral-associated cancers and disorders | Lifetime | 890 | CN 39 | 95.90 |
| FOXO transcription factor regulation | Lifetime | 118 | CN 12 | 93.81 |
| Autophagy in Disease and Therapy | Lifetime | 950 | CN 191 | 94.89 |
| Inflammasome and immune disorders | Lifetime | 688 | CN 72 | 94.43 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 461 | CN 65 | 92.77 |
| Phagocytosis and Immune Regulation | Lifetime | 521 | CN 31 | 92.98 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 415 | CN 35 | 92.86 |
| Hedgehog Signaling Pathway Studies | Lifetime | 774 | CN 23 | 91.61 |
| Clusterin in disease pathology | Lifetime | 481 | CN 41 | 62.94 |
| RNA modifications and cancer | 2021-2025 | 5 | CN 4 | 99.94 |
| Cancer-related molecular mechanisms research | 2021-2025 | 7 | CN 4 | 99.92 |
| Immune Cell Function and Interaction | 2021-2025 | 7 | CN 2 | 99.66 |
| MicroRNA in disease regulation | 2021-2025 | 9 | CN 5 | 99.75 |
| Circular RNAs in diseases | 2021-2025 | 5 | CN 1 | 99.77 |
| Epigenetics and DNA Methylation | 2021-2025 | 11 | CN 4 | 99.38 |
| Ferroptosis and cancer prognosis | 2021-2025 | 10 | CN 6 | 99.80 |
| Cancer-related gene regulation | 2021-2025 | 9 | CN 5 | 99.22 |
| RNA Research and Splicing | 2021-2025 | 22 | CN 5 | 99.01 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 12 | CN 1 | 99.05 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 46 | CN 22 | 98.13 |
| CAR-T cell therapy research | 2021-2025 | 117 | CN 3 | 99.21 |
| Immune cells in cancer | 2021-2025 | 99 | CN 59 | 97.57 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 268 | CN 43 | 98.97 |
| Ubiquitin and proteasome pathways | 2021-2025 | 64 | CN 29 | 96.32 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 129 | CN 30 | 95.74 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 225 | CN 8 | 97.76 |
| Galectins and Cancer Biology | 2021-2025 | 49 | CN 10 | 93.50 |
| Extracellular vesicles in disease | 2021-2025 | 327 | CN 200 | 95.00 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 326 | CN 14 | 96.51 |
| Immunotherapy and Immune Responses | 2021-2025 | 454 | CN 126 | 94.67 |
| Inflammasome and immune disorders | 2021-2025 | 170 | CN 84 | 93.59 |
| Peptidase Inhibition and Analysis | 2021-2025 | 276 | CN 62 | 94.23 |
| T-cell and B-cell Immunology | 2021-2025 | 276 | CN 29 | 92.84 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 180 | CN 79 | 89.10 |
| Viral-associated cancers and disorders | 2021-2025 | 210 | CN 33 | 92.46 |
| Hematopoietic Stem Cell Transplantation | 2021-2025 | 522 | CN 42 | 91.67 |
| Acute Kidney Injury Research | 2021-2025 | 338 | CN 78 | 88.20 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 214 | CN 14 | 88.42 |
| Biochemical and Molecular Research | 2021-2025 | 266 | CN 54 | 80.37 |
| Congenital Anomalies and Fetal Surgery | 2021-2025 | 364 | CN 46 | 82.07 |
| Advanced Breast Cancer Therapies | 2021-2025 | 935 | CN 103 | 83.85 |
| Adenosine and Purinergic Signaling | 2021-2025 | 317 | CN 64 | 78.97 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 755 | CN 57 | 82.93 |
| Kruppel-like factors research | 2021-2025 | 180 | CN 57 | 78.77 |
| Parasitic infections in humans and animals | 2021-2025 | 253 | CN 58 | 79.22 |
| Microtubule and mitosis dynamics | 2021-2025 | 584 | CN 81 | 73.53 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 451 | CN 179 | 70.10 |
| Machine Learning in Bioinformatics | 2021-2025 | 773 | CN 367 | 67.88 |
| Phagocytosis and Immune Regulation | 2021-2025 | 930 | CN 403 | 65.71 |
| Brucella: diagnosis, epidemiology, treatment | 2021-2025 | 359 | CN 111 | 62.92 |
| Fibroblast Growth Factor Research | 2021-2025 | 774 | CN 233 | 60.84 |
| FOXO transcription factor regulation | 2021-2025 | 215 | CN 73 | 56.03 |
| Nitrogen and Sulfur Effects on Brassica | 2021-2025 | 878 | CN 371 | 35.78 |
| Peanut Plant Research Studies | 2021-2025 | 957 | CN 382 | 32.75 |
